Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 54.55

-3.6%

3:27 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (5971)	3/20/2002 10:58:53 AM
From: aknahow	Read Replies (1) of 52153

<<<<But of course it does mean that trials would take that much longer (which of course is mainly why companies have always pushed for the use of surrogate endpoints instead).>>> True but if the FDA is now apparently not convinced that tumor shrinkage is good enough to merit approval even in cancer trials for different types of drugs, other endpoints may be found. Living longer does not necessarily mean that the trials have that as an endpoint but rather that the trials don't choose shrinkage when that is not apt to be the result. Again I am not able to do justice to the articles so any with an interest in this area should read them in the March issue of The Scientist.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next